1
|
Sartor AO, Oudard S, Ozguroglu M, Hansen S, Machiels JH, Shen L, De Bono JS. Survival benefit from first docetaxel treatment for cabazitaxel plus prednisone compared with mitoxantrone plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in the TROPIC trial. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4525] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
2
|
De Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JH, Shen L, Sartor AO. A subgroup analysis of the TROPIC trial exploring reason for discontinuation of prior docetaxel and survival outcome of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4526] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
3
|
Grünwald V, Karakiewicz PI, Bavbek SE, Miller K, Machiels JH, Lee S, Larkin JMG, Bono P, Rha SY, Castellano DE, Blank CU, Knox JJ, Hawkins R, Yuan RR, Rosamilia M, Booth JL, Bodrogi I. Final results of the international, expanded-access program of everolimus in patients with advanced renal cell carcinoma who progress after prior vascular endothelial growth factor receptor–tyrosine kinase inhibitor (VEGFr-TKI) therapy. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4601] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
4
|
Ozguroglu M, Oudard S, Sartor AO, Hansen S, Machiels JH, Shen L, De Bono JS. Impact of G-CSF prophylaxis on the occurrence of neutropenia in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e15131] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
5
|
Crepel M, Escudier BJ, Machiels JH, Staehler MD, Ravaud A, Gravis G, Joly F, Chevreau C, Zini L, Lang H, Salomon L, Bigot P, Rigaud J, Patard J. Comparison of two major prognostic models for patients with metastatic renal cell carcinoma treated in the contemporary era of targeted therapies. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4660] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
6
|
Guigay J, Fayette J, Dillies A, Sire C, Kerger JN, Tennevet I, Machiels JH, Zanetta S, Pointreau Y, Bozec Le Moal L, Brugel Ribere L, Henry S, Temam S. Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): First results of phase II trial GORTEC 2008-03. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.5567] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
7
|
Seront E, Sautois B, Rottey S, D'Hondt LA, Canon J, Vandenbulcke J, Whenham N, Goeminne JC, Feron O, Machiels JH. Phase II trial of everolimus monotherapy in the palliative treatment of patients with metastatic transitional cell carcinoma (TCC) after failure of platinum-based therapy: Activity and biomarkers. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4622] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
8
|
Ozguroglu M, Oudard S, Sartor AO, Hansen S, Machiels JH, Shen L, De Bono JS. Effect of G-CSF prophylaxis on the occurrence of neutropenia in men receiving cabazitaxel plus prednisone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in the TROPIC study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.7_suppl.144] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
144^ Background: The phase III TROPIC study showed that cabazitaxel plus prednisone (CbzP) improves survival compared with mitoxantrone plus prednisone (MP) in men with mCRPC who progressed after docetaxel-based therapy (HR 0.70; p<0.001; Lancet 2010;376:1147). In this study, a higher percentage of men in the CbzP group had grade ≥3 neutropenia (81.7% versus 58.0%). We analyzed the effect of G-CSF use on the occurrence of grade ≥3 neutropenia. Methods: 755 men with mCRPC who progressed during or after a docetaxel-containing regimen were randomized to receive 10 mg of oral prednisone daily and either 12 mg/m2 of mitoxantrone or 25 mg/m2 of cabazitaxel every 3 weeks. Primary prophylaxis with G-CSF was not permitted at cycle 1, but was allowed after the first occurrence of neutropenia either lasting ≥7 days or complicated by fever >38.5°C, or fever >38.1°C for three observations during a 24- hour period, or infection. We analyzed the effect of G-CSF use on the occurrence of neutropenia in cycles 2–10. G-CSF use was defined as either prophylactic (administered within 3 days of chemotherapy dose) or therapeutic (administered more than 3 days after chemotherapy dose). Results: A total of3246 cycles (1881 CbzP; 1365 MP) were administered from cycle 2 onward. No G-CSF was used in 2,322 cycles (1144 CbzP; 1178 MP) and the percentage of these cycles with grade ≥3 neutropenia was similar between the groups (44.6% CbzP; 38.4% MP). G-CSF was used in more cycles in the CbzP group as prophylaxis (588 CbzP; 118 MP; chi-square P<0.0001) and therapeutically (149 CbzP; 69 MP; P=0.0013). The percentage of CbzP cycles with grade ≥3 neutropenia was lower when G-CSF was used early as prophylaxis versus using it later as a therapeutic modality (24.7% versus 57.7%; P<0.0001). A reduction in grade ≥3 neutropenia favoring prophylactic versus therapeutic G-CSF was also observed in the MP group (9.3% versus 33.3%; P<0.0001). Conclusions: The appropriate and timely use of G-CSF as prophylaxis reduces the occurrence of neutropenia in men receiving CbzP for mCRPC. Adherence to current guidelines on the use of G-CSF is recommended to manage this predictable side effect. [Table: see text]
Collapse
Affiliation(s)
- M. Ozguroglu
- Istanbul University Cerrahpaşa Medical Faculty Department of Medical Oncology, Istanbul, Turkey; Medical Oncology Department, Georges Pompidou European Hospital, Paris, France; Tulane University, New Orleans, LA; Odense University Hospital, Odense, Denmark; Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium; sanofi-aventis, Malvern, PA; The Royal Marsden Hospital, Sutton, United Kingdom
| | - S. Oudard
- Istanbul University Cerrahpaşa Medical Faculty Department of Medical Oncology, Istanbul, Turkey; Medical Oncology Department, Georges Pompidou European Hospital, Paris, France; Tulane University, New Orleans, LA; Odense University Hospital, Odense, Denmark; Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium; sanofi-aventis, Malvern, PA; The Royal Marsden Hospital, Sutton, United Kingdom
| | - A. O. Sartor
- Istanbul University Cerrahpaşa Medical Faculty Department of Medical Oncology, Istanbul, Turkey; Medical Oncology Department, Georges Pompidou European Hospital, Paris, France; Tulane University, New Orleans, LA; Odense University Hospital, Odense, Denmark; Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium; sanofi-aventis, Malvern, PA; The Royal Marsden Hospital, Sutton, United Kingdom
| | - S. Hansen
- Istanbul University Cerrahpaşa Medical Faculty Department of Medical Oncology, Istanbul, Turkey; Medical Oncology Department, Georges Pompidou European Hospital, Paris, France; Tulane University, New Orleans, LA; Odense University Hospital, Odense, Denmark; Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium; sanofi-aventis, Malvern, PA; The Royal Marsden Hospital, Sutton, United Kingdom
| | - J. H. Machiels
- Istanbul University Cerrahpaşa Medical Faculty Department of Medical Oncology, Istanbul, Turkey; Medical Oncology Department, Georges Pompidou European Hospital, Paris, France; Tulane University, New Orleans, LA; Odense University Hospital, Odense, Denmark; Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium; sanofi-aventis, Malvern, PA; The Royal Marsden Hospital, Sutton, United Kingdom
| | - L. Shen
- Istanbul University Cerrahpaşa Medical Faculty Department of Medical Oncology, Istanbul, Turkey; Medical Oncology Department, Georges Pompidou European Hospital, Paris, France; Tulane University, New Orleans, LA; Odense University Hospital, Odense, Denmark; Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium; sanofi-aventis, Malvern, PA; The Royal Marsden Hospital, Sutton, United Kingdom
| | - J. S. De Bono
- Istanbul University Cerrahpaşa Medical Faculty Department of Medical Oncology, Istanbul, Turkey; Medical Oncology Department, Georges Pompidou European Hospital, Paris, France; Tulane University, New Orleans, LA; Odense University Hospital, Odense, Denmark; Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium; sanofi-aventis, Malvern, PA; The Royal Marsden Hospital, Sutton, United Kingdom
| | | |
Collapse
|
9
|
Grunwald V, Bodrogi I, Miller K, Machiels JH, Lee S, Chowdhury S, Yuan R, Rosamilia M, Booth JL, Karakiewicz PI. Everolimus in patients with metastatic renal cell carcinoma (mRCC) who are intolerant of or have progressed after prior vascular endothelial growth factor receptor–tyrosine kinase inhibitor (VEGFr-TKI) therapy: An international expanded access program (EAP). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.7_suppl.314] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
314 Background: The mammalian target of rapamycin (mTOR) inhibitor everolimus is the first agent to show efficacy in a randomized, controlled phase III trial in patients with mRCC after progression on VEGFr-TKIs (RECORD-1). Progression-free survival (PFS) was significantly improved (4.9 vs 1.9 months) and the risk of disease progression was reduced by 67% with everolimus compared with placebo. To fulfill an unmet medical need, everolimus was offered globally in this EAP. Presented here are preliminary results on 605 patients. Methods: The program began in July 2008 (ClinicalTrials.gov: NCT00655252 ; EudraCT: 2007-005460-28), and since then over 1,000 patients in 34 countries have been enrolled. Patients with clear cell and non–clear cell mRCC who failed or became intolerant of VEGFr-TKIs received daily oral doses of everolimus with investigator assessment every 3 months. Results: Data were collected for 605 patients who had discontinued treatment as of January 15, 2010. Evaluable patients had a mean age of 63 years, and most (94%) had progressed after prior VEGFr-TKI therapy. The adverse event (AE) profile did not differ significantly from that reported in the RECORD-1 trial. Most frequently reported grade 3–4 AEs were anemia (6.1%), stomatitis (4.6%), fatigue (4.6%), hyperglycemia (4.0%), and infection (3.6%). Grade 3–4 noninfectious pneumonitis was reported in 2.8%. Best overall response was stable disease, which was evident in 42% of patients. Conclusions: The EAP has allowed patients with mRCC access to everolimus before marketing approval. The rapid enrollment rate of this EAP confirms the unmet medical need after failure of VEGFr-TKIs. Everolimus has shown good tolerability, and no new safety issues have been identified. The investigator-assessed response rate is consistent with that reported in the RECORD-1 trial. The EAP provides an efficient framework for the development of other programs for innovative anticancer agents in patients without satisfactory therapeutic options. [Table: see text]
Collapse
Affiliation(s)
- V. Grunwald
- Hannover Medical School, Hannover, Germany; National Institute of Oncology, Budapest, Hungary; Department of Urology, Charité-University Medicine Berlin, Berlin, Germany; Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium; Seoul National University Hospital, Seoul, South Korea; Guy's and St. Thomas' Hospital, London, United Kingdom; Novartis Pharmaceuticals, Florham Park, NJ; University of Medicine and Dentistry of New Jersey, Florham Park, NJ; Novartis Oncology
| | - I. Bodrogi
- Hannover Medical School, Hannover, Germany; National Institute of Oncology, Budapest, Hungary; Department of Urology, Charité-University Medicine Berlin, Berlin, Germany; Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium; Seoul National University Hospital, Seoul, South Korea; Guy's and St. Thomas' Hospital, London, United Kingdom; Novartis Pharmaceuticals, Florham Park, NJ; University of Medicine and Dentistry of New Jersey, Florham Park, NJ; Novartis Oncology
| | - K. Miller
- Hannover Medical School, Hannover, Germany; National Institute of Oncology, Budapest, Hungary; Department of Urology, Charité-University Medicine Berlin, Berlin, Germany; Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium; Seoul National University Hospital, Seoul, South Korea; Guy's and St. Thomas' Hospital, London, United Kingdom; Novartis Pharmaceuticals, Florham Park, NJ; University of Medicine and Dentistry of New Jersey, Florham Park, NJ; Novartis Oncology
| | - J. H. Machiels
- Hannover Medical School, Hannover, Germany; National Institute of Oncology, Budapest, Hungary; Department of Urology, Charité-University Medicine Berlin, Berlin, Germany; Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium; Seoul National University Hospital, Seoul, South Korea; Guy's and St. Thomas' Hospital, London, United Kingdom; Novartis Pharmaceuticals, Florham Park, NJ; University of Medicine and Dentistry of New Jersey, Florham Park, NJ; Novartis Oncology
| | - S. Lee
- Hannover Medical School, Hannover, Germany; National Institute of Oncology, Budapest, Hungary; Department of Urology, Charité-University Medicine Berlin, Berlin, Germany; Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium; Seoul National University Hospital, Seoul, South Korea; Guy's and St. Thomas' Hospital, London, United Kingdom; Novartis Pharmaceuticals, Florham Park, NJ; University of Medicine and Dentistry of New Jersey, Florham Park, NJ; Novartis Oncology
| | - S. Chowdhury
- Hannover Medical School, Hannover, Germany; National Institute of Oncology, Budapest, Hungary; Department of Urology, Charité-University Medicine Berlin, Berlin, Germany; Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium; Seoul National University Hospital, Seoul, South Korea; Guy's and St. Thomas' Hospital, London, United Kingdom; Novartis Pharmaceuticals, Florham Park, NJ; University of Medicine and Dentistry of New Jersey, Florham Park, NJ; Novartis Oncology
| | - R. Yuan
- Hannover Medical School, Hannover, Germany; National Institute of Oncology, Budapest, Hungary; Department of Urology, Charité-University Medicine Berlin, Berlin, Germany; Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium; Seoul National University Hospital, Seoul, South Korea; Guy's and St. Thomas' Hospital, London, United Kingdom; Novartis Pharmaceuticals, Florham Park, NJ; University of Medicine and Dentistry of New Jersey, Florham Park, NJ; Novartis Oncology
| | - M. Rosamilia
- Hannover Medical School, Hannover, Germany; National Institute of Oncology, Budapest, Hungary; Department of Urology, Charité-University Medicine Berlin, Berlin, Germany; Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium; Seoul National University Hospital, Seoul, South Korea; Guy's and St. Thomas' Hospital, London, United Kingdom; Novartis Pharmaceuticals, Florham Park, NJ; University of Medicine and Dentistry of New Jersey, Florham Park, NJ; Novartis Oncology
| | - J. L. Booth
- Hannover Medical School, Hannover, Germany; National Institute of Oncology, Budapest, Hungary; Department of Urology, Charité-University Medicine Berlin, Berlin, Germany; Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium; Seoul National University Hospital, Seoul, South Korea; Guy's and St. Thomas' Hospital, London, United Kingdom; Novartis Pharmaceuticals, Florham Park, NJ; University of Medicine and Dentistry of New Jersey, Florham Park, NJ; Novartis Oncology
| | - P. I. Karakiewicz
- Hannover Medical School, Hannover, Germany; National Institute of Oncology, Budapest, Hungary; Department of Urology, Charité-University Medicine Berlin, Berlin, Germany; Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium; Seoul National University Hospital, Seoul, South Korea; Guy's and St. Thomas' Hospital, London, United Kingdom; Novartis Pharmaceuticals, Florham Park, NJ; University of Medicine and Dentistry of New Jersey, Florham Park, NJ; Novartis Oncology
| |
Collapse
|
10
|
Machiels JH, Subramanian S, Ruzsa A, Repassy G, Lifrenko I, Flygare A, Sorensen P, Ehrnrooth E, Baadsgaard O, Clement PM. An open-label, randomized, phase III trial of zalutumumab, a human monoclonal EGF receptor (EGFr) antibody, versus best supportive care, in patients with noncurable squamous cell carcinoma (SCCHN) of the head and neck who have failed standard platinum-based chemotherapy (ZALUTE). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.18_suppl.lba5506] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
LBA5506 Background: Zalutumumab is a novel, fully human IgG1 mAb targeting the EGFr that has shown encouraging activity in SCCHN. Methods: Patients with noncurable SCCHN with an ECOG PS of 0-2 and centrally documented radiographic progressive disease (PD) within 6 months after platinum-therapy were randomized between zalutumumab monotherapy and best supportive care (BSC) in a 2:1 ratio. Stratification parameter was ECOG PS. Methotrexate (MTX) was allowed in the BSC arm only. Individual dose-titration of zalutumumab was applied (max. exposure 16 mg/kg). The primary endpoint was overall survival (OS), with progression free survival (PFS) as the only secondary endpoint to be compared between groups, using log-rank test. 231 deaths were required to statistically differentiate OS between groups with 80% power. Results: 286 patients (34F, 252M) were randomized. The median age was 57 years (range 18-78), 65% had distant metastasis and 17% were ECOG PS 2, all similar between groups. 78% of patients in BSC arm received MTX. Although a median OS of 6.7 months was observed in the zalutumumab group compared to 5.2 in the BSC group, this was not statistically significant (p=0.065). A clear improvement in PFS (P=0.001) was demonstrated. Zalutumumab showed a safety profile as expected within this drug class. Conclusions: This is the first controlled study to demonstrate that an EGFr-targeted antibody given as monotherapy induces a clinically meaningful improvement in PFS in patients with SSCHN who have failed platinum-based chemotherapy. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- J. H. Machiels
- Cliniques Universitaires Saint-Luc, Universitá Catholique de Louvain, Brussels, Belgium; N. N. Blokhin Russian Cancer Research Center, Moscow, Russia; Zala Megyei Korhaz, Onkologia Osztaly, Zalaegerszeg-Pozva, Hungary; Semmelweis University, Budapest, Hungary; Kursk Regional Oncology Dispencary, Kursk, Russia; Genmab, Copenhagen, Denmark; Department of General Medical Oncology, University Hospitals Leuven and Catholic University of Leuven, Leuven, Belgium
| | - S. Subramanian
- Cliniques Universitaires Saint-Luc, Universitá Catholique de Louvain, Brussels, Belgium; N. N. Blokhin Russian Cancer Research Center, Moscow, Russia; Zala Megyei Korhaz, Onkologia Osztaly, Zalaegerszeg-Pozva, Hungary; Semmelweis University, Budapest, Hungary; Kursk Regional Oncology Dispencary, Kursk, Russia; Genmab, Copenhagen, Denmark; Department of General Medical Oncology, University Hospitals Leuven and Catholic University of Leuven, Leuven, Belgium
| | - A. Ruzsa
- Cliniques Universitaires Saint-Luc, Universitá Catholique de Louvain, Brussels, Belgium; N. N. Blokhin Russian Cancer Research Center, Moscow, Russia; Zala Megyei Korhaz, Onkologia Osztaly, Zalaegerszeg-Pozva, Hungary; Semmelweis University, Budapest, Hungary; Kursk Regional Oncology Dispencary, Kursk, Russia; Genmab, Copenhagen, Denmark; Department of General Medical Oncology, University Hospitals Leuven and Catholic University of Leuven, Leuven, Belgium
| | - G. Repassy
- Cliniques Universitaires Saint-Luc, Universitá Catholique de Louvain, Brussels, Belgium; N. N. Blokhin Russian Cancer Research Center, Moscow, Russia; Zala Megyei Korhaz, Onkologia Osztaly, Zalaegerszeg-Pozva, Hungary; Semmelweis University, Budapest, Hungary; Kursk Regional Oncology Dispencary, Kursk, Russia; Genmab, Copenhagen, Denmark; Department of General Medical Oncology, University Hospitals Leuven and Catholic University of Leuven, Leuven, Belgium
| | - I. Lifrenko
- Cliniques Universitaires Saint-Luc, Universitá Catholique de Louvain, Brussels, Belgium; N. N. Blokhin Russian Cancer Research Center, Moscow, Russia; Zala Megyei Korhaz, Onkologia Osztaly, Zalaegerszeg-Pozva, Hungary; Semmelweis University, Budapest, Hungary; Kursk Regional Oncology Dispencary, Kursk, Russia; Genmab, Copenhagen, Denmark; Department of General Medical Oncology, University Hospitals Leuven and Catholic University of Leuven, Leuven, Belgium
| | - A. Flygare
- Cliniques Universitaires Saint-Luc, Universitá Catholique de Louvain, Brussels, Belgium; N. N. Blokhin Russian Cancer Research Center, Moscow, Russia; Zala Megyei Korhaz, Onkologia Osztaly, Zalaegerszeg-Pozva, Hungary; Semmelweis University, Budapest, Hungary; Kursk Regional Oncology Dispencary, Kursk, Russia; Genmab, Copenhagen, Denmark; Department of General Medical Oncology, University Hospitals Leuven and Catholic University of Leuven, Leuven, Belgium
| | - P. Sorensen
- Cliniques Universitaires Saint-Luc, Universitá Catholique de Louvain, Brussels, Belgium; N. N. Blokhin Russian Cancer Research Center, Moscow, Russia; Zala Megyei Korhaz, Onkologia Osztaly, Zalaegerszeg-Pozva, Hungary; Semmelweis University, Budapest, Hungary; Kursk Regional Oncology Dispencary, Kursk, Russia; Genmab, Copenhagen, Denmark; Department of General Medical Oncology, University Hospitals Leuven and Catholic University of Leuven, Leuven, Belgium
| | - E. Ehrnrooth
- Cliniques Universitaires Saint-Luc, Universitá Catholique de Louvain, Brussels, Belgium; N. N. Blokhin Russian Cancer Research Center, Moscow, Russia; Zala Megyei Korhaz, Onkologia Osztaly, Zalaegerszeg-Pozva, Hungary; Semmelweis University, Budapest, Hungary; Kursk Regional Oncology Dispencary, Kursk, Russia; Genmab, Copenhagen, Denmark; Department of General Medical Oncology, University Hospitals Leuven and Catholic University of Leuven, Leuven, Belgium
| | - O. Baadsgaard
- Cliniques Universitaires Saint-Luc, Universitá Catholique de Louvain, Brussels, Belgium; N. N. Blokhin Russian Cancer Research Center, Moscow, Russia; Zala Megyei Korhaz, Onkologia Osztaly, Zalaegerszeg-Pozva, Hungary; Semmelweis University, Budapest, Hungary; Kursk Regional Oncology Dispencary, Kursk, Russia; Genmab, Copenhagen, Denmark; Department of General Medical Oncology, University Hospitals Leuven and Catholic University of Leuven, Leuven, Belgium
| | - P. M. Clement
- Cliniques Universitaires Saint-Luc, Universitá Catholique de Louvain, Brussels, Belgium; N. N. Blokhin Russian Cancer Research Center, Moscow, Russia; Zala Megyei Korhaz, Onkologia Osztaly, Zalaegerszeg-Pozva, Hungary; Semmelweis University, Budapest, Hungary; Kursk Regional Oncology Dispencary, Kursk, Russia; Genmab, Copenhagen, Denmark; Department of General Medical Oncology, University Hospitals Leuven and Catholic University of Leuven, Leuven, Belgium
| |
Collapse
|
11
|
Seront E, Rottey S, Sautois B, D'Hondt LA, Canon JR, Vandenbulcke J, Whenham N, Goeminne J, Verhoeven D, Machiels JH. A single arm, multicenter, phase II trial of everolimus as monotherapy in the palliative treatment of patients with locally advanced or metastatic transitional cell carcinoma after failure of platinum-based chemotherapy. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e15087] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
12
|
Vallbohmer D, Grimminger PP, Yang D, Danenberg KD, Danenberg P, Arnold D, Machiels JH, Roedel C, Velenik V, Lenz H. Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in advanced rectal cancer. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.3563] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
13
|
De Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JH, Shen L, Matthews P, Sartor AO. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.4508] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
14
|
Schmitz S, Kaminsky-Forrett M, Henry S, Zanetta S, Geoffrois L, Bompas E, Moxhon A, Guigay J, Machiels JH. Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: GORTEC 2008-02. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.5500] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
15
|
Hu-Lieskovan S, Yang D, Grimminger PP, Arnold D, Dellas K, Machiels JH, Roedel C, Velenik V, Lenz H, Vallbohmer D. Use of EGF a+61G and TS-5'UTR 2R/3R polymorphisms to predict complete pathologic response in locally advanced rectal cancer patients undergoing preoperative cetuximab-based chemoradiation followed by surgery. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.3641] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
16
|
Vermorken JB, Machiels JH, Rottey S, Thurm HC, Pelling K, Lahogue A. Phase Ib study evaluating the combination of BIBW 2992 with two different standard chemotherapy regimens, cisplatin/paclitaxel (PT) and cisplatin/5-FU (PF), in patients with advanced solid tumors. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e13521] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
17
|
Machiels JH, Henry S, Zanetta S, Kaminsky M, Michoux N, Bompas E, Dillies A, Faivre S, Schmitz S, Guigay J. Phase II study of sunitinib in patients with recurrent and/or metastatic squamous head and neck carcinoma: The GORTEC 2006–01 study. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.6024] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6024 Background: Up to 90% of head and neck squamous cell carcinoma (HNSCC) express the vascular endothelial growth factor (VEGF) or the VEGF receptors (VEGFR) 1–3. Angiogenic factors could have prognostic implication making anti-angiogenic therapies an attractive treatment modality. Sunitinib inhibits multiple tyrosine kinase receptors including VEGFR1–3 and PDGFR. Methods: Palliative HNSCC in PD after platinum therapy received sunitinib 37.5 mg/day continuously. The primary endpoint was the disease control rate (SD, PR, CR) at 6–8 wks. A two-stage design was used (Simon; a = 0.15,b = 0.10, H0 = 10%, H1 = 25%) meaning that at least 6 patients out of 37 should achieve a SD. Dynamic contrast enhanced (DCE) magnetic resonance (MR) perfusion-weighted imaging before and 6 wks after treatment initiation was performed on a 3T system. Results: 37 pts (M/F:28/9;PS 0/1:5/32) were included.11 pts were not evaluable by imaging due to rapid clinical PD (7 pts) or toxicity (4 pts) and were considered in PD.PR was found in 1 pts, SD in 18, and PD in 18 (RECIST). Among the SD, 6 had a minor response and 5 had an unconfirmed PR (maximum % reduction in sum of the largest diameters: 2%, 4%, 7%, 10%, 16%, 17%, 30%, 45%, 48%, 65%, 73%). PR could not be confirmed due to PD within 4 wks (3 pts) or treatment termination due to toxicity (2 pts). 4 pts had MR DCE monitoring. In 3, a significant decrease in the volume transfer constant Ktrans measuring the tumor perfusion and endothelial permeability was found during sunitinib treatment. The main Gr3–4 toxicities (N pts) were fatigue (12), tumor bleedings (2), LVEF decrease (2), hypertension (2). Gr5 tumor bleedings occurred in 4 pts. Other local complications included apparition/worsening of tumor skin ulceration or tumor fistula in 15 pts. Conclusions: This trial met its primary endpoint with modest activity of sunitinib in HNSSC. The rate of complications (i.e., fatal bleedings) outlines the importance of a better patient selection. DCE-MRI may be useful to predict response. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. H. Machiels
- Université Catholique de Louvain, Brussels, Belgium; Mont-Godinne, UCL-Yvoir; Clinique St-Elisabeth, Namur, Belgium; Centre George-François Leclerc, Dijon, France; Centre Alexis Vautrin, Nancy, France; Centre René Gauducheau, Saint-Herblain, France; Centre Jean Perrin, Clermont Ferrand, France; AP-HP, Hôpital Beaujon, Paris, France; Institut Gustave Roussy, Villejuif, France
| | - S. Henry
- Université Catholique de Louvain, Brussels, Belgium; Mont-Godinne, UCL-Yvoir; Clinique St-Elisabeth, Namur, Belgium; Centre George-François Leclerc, Dijon, France; Centre Alexis Vautrin, Nancy, France; Centre René Gauducheau, Saint-Herblain, France; Centre Jean Perrin, Clermont Ferrand, France; AP-HP, Hôpital Beaujon, Paris, France; Institut Gustave Roussy, Villejuif, France
| | - S. Zanetta
- Université Catholique de Louvain, Brussels, Belgium; Mont-Godinne, UCL-Yvoir; Clinique St-Elisabeth, Namur, Belgium; Centre George-François Leclerc, Dijon, France; Centre Alexis Vautrin, Nancy, France; Centre René Gauducheau, Saint-Herblain, France; Centre Jean Perrin, Clermont Ferrand, France; AP-HP, Hôpital Beaujon, Paris, France; Institut Gustave Roussy, Villejuif, France
| | - M. Kaminsky
- Université Catholique de Louvain, Brussels, Belgium; Mont-Godinne, UCL-Yvoir; Clinique St-Elisabeth, Namur, Belgium; Centre George-François Leclerc, Dijon, France; Centre Alexis Vautrin, Nancy, France; Centre René Gauducheau, Saint-Herblain, France; Centre Jean Perrin, Clermont Ferrand, France; AP-HP, Hôpital Beaujon, Paris, France; Institut Gustave Roussy, Villejuif, France
| | - N. Michoux
- Université Catholique de Louvain, Brussels, Belgium; Mont-Godinne, UCL-Yvoir; Clinique St-Elisabeth, Namur, Belgium; Centre George-François Leclerc, Dijon, France; Centre Alexis Vautrin, Nancy, France; Centre René Gauducheau, Saint-Herblain, France; Centre Jean Perrin, Clermont Ferrand, France; AP-HP, Hôpital Beaujon, Paris, France; Institut Gustave Roussy, Villejuif, France
| | - E. Bompas
- Université Catholique de Louvain, Brussels, Belgium; Mont-Godinne, UCL-Yvoir; Clinique St-Elisabeth, Namur, Belgium; Centre George-François Leclerc, Dijon, France; Centre Alexis Vautrin, Nancy, France; Centre René Gauducheau, Saint-Herblain, France; Centre Jean Perrin, Clermont Ferrand, France; AP-HP, Hôpital Beaujon, Paris, France; Institut Gustave Roussy, Villejuif, France
| | - A. Dillies
- Université Catholique de Louvain, Brussels, Belgium; Mont-Godinne, UCL-Yvoir; Clinique St-Elisabeth, Namur, Belgium; Centre George-François Leclerc, Dijon, France; Centre Alexis Vautrin, Nancy, France; Centre René Gauducheau, Saint-Herblain, France; Centre Jean Perrin, Clermont Ferrand, France; AP-HP, Hôpital Beaujon, Paris, France; Institut Gustave Roussy, Villejuif, France
| | - S. Faivre
- Université Catholique de Louvain, Brussels, Belgium; Mont-Godinne, UCL-Yvoir; Clinique St-Elisabeth, Namur, Belgium; Centre George-François Leclerc, Dijon, France; Centre Alexis Vautrin, Nancy, France; Centre René Gauducheau, Saint-Herblain, France; Centre Jean Perrin, Clermont Ferrand, France; AP-HP, Hôpital Beaujon, Paris, France; Institut Gustave Roussy, Villejuif, France
| | - S. Schmitz
- Université Catholique de Louvain, Brussels, Belgium; Mont-Godinne, UCL-Yvoir; Clinique St-Elisabeth, Namur, Belgium; Centre George-François Leclerc, Dijon, France; Centre Alexis Vautrin, Nancy, France; Centre René Gauducheau, Saint-Herblain, France; Centre Jean Perrin, Clermont Ferrand, France; AP-HP, Hôpital Beaujon, Paris, France; Institut Gustave Roussy, Villejuif, France
| | - J. Guigay
- Université Catholique de Louvain, Brussels, Belgium; Mont-Godinne, UCL-Yvoir; Clinique St-Elisabeth, Namur, Belgium; Centre George-François Leclerc, Dijon, France; Centre Alexis Vautrin, Nancy, France; Centre René Gauducheau, Saint-Herblain, France; Centre Jean Perrin, Clermont Ferrand, France; AP-HP, Hôpital Beaujon, Paris, France; Institut Gustave Roussy, Villejuif, France
| |
Collapse
|
18
|
Machiels JH, Debucquoy A, Gevaert O, Daemen A, Sempoux C, McBride W, Stroh C, Vlassak S, Haustermans K. Prediction of pathological response to preoperative chemoradiotherapy with cetuximab in rectal cancer. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.4095] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
19
|
Hutson TE, Davis ID, Machiels JH, de Souza PL, Baker K, Bordogna W, Westlund R, Crofts T, Pandite L, Figlin RA. Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.5046] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
20
|
Machiels JH, Mazzeo F, Clausse M, Filleul B, Marcelis L, Honhon B, D’Hondt L, Dopchie C, Bonny M, Kerger J. Phase III trial of docetaxel (D), estramustine (E), and prednisone versus docetaxel plus prednisone in patients with metastatic hormone-refractory prostate cancer (HRPC). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.5067] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5067 Background: D alone or in combination with E improves survival of pts with metastatic HRPC. Whether E is necessary in combination with D is controversial. Preclinical data suggest a synergistic activity between D and E. Phase II as well as small randomized trials support this hypothesis, although indirect comparisons between the large phase III studies are not in favor of D/E combination. We conducted a randomized, prospective, multicentric study to compare D versus D/E. Methods: 150 metastatic HRPC were randomized (minimisation, stratification parameters: PSA level, ECOG, previous E use (38 pts), and center) between D (35 mg/m2 on day 2 and 9, every 3 wks) and D in combination with E (280 mg PO tid on days 1 to 5 and 8 to 12, coumadin 1mg/d). E was the only difference between the two treatment arms. All the pts received prednisone (10 mg/d). The primary endpoint was PSA response rate (decrease in PSA > 50% from baseline) and the study was powered to detect a 25% difference in PSA response rate. Results: No significant difference was found for PSA response (D/E: 50/68 (73%); D: 48/69 (69%)), time to PSA progression (median 205 days for D/E and 210 days for D), duration of PSA response (median 185 days for D/E and 220 days for D), progression-free survival (median 186 days for D/E and 195 days for D), response rate according to RECIST, and overall survival (median 617 days for D/E and 629 days for D). PSA < 4 ngr/mL occurred in 28/68 pts (41%) in D/E and in 17/69 (25%) in D (p=0.04). More pts had at least one grade 3/4 NCI-CTC toxicity in D/E (33/75 pts; 45%) compared to D (16/75 pts; 21%) (p=0.003). The main difference was grade 3/4 digestive toxicity (D/E:15% and D:4%; p=0.017). Serious adverse events were reported more frequently in D/E than D: 20 vs 9 (p=0.03). In D/E, the most frequent grade 3/4 toxicities were digestive (15%) and venous thrombosis (12%). In D, the most frequent grade 3/4 toxicity was anemia (9%) and venous thrombosis (8%). Conclusions: Our study did not show any clinically relevant advantage in term of efficacy for the addition of E to D. Both regimens were well-tolerated although the toxicity profile was in favor of D without E. Our study does not support the addition of E to D to treat pts with HPRC. [Table: see text]
Collapse
Affiliation(s)
- J. H. Machiels
- Medical Oncology, Universite catholique de Louvain, Brussels, Brabant, Belgium; Clinique Saint Luc, Bouge, Belgium; Hôpital de Jolimont, Haine-St–Paul, Belgium; CHIREC Site Parc Leopold, Brussels, Belgium; Hôpital St-Joseph, Gilly, Belgium; Clinique Notre Dame, Charleroi, Belgium; Clinique Notre Dame, Tournai, Belgium; UCL Mont-Godinne and St-Elisabeth, Yvoir and Namur, Belgium
| | - F. Mazzeo
- Medical Oncology, Universite catholique de Louvain, Brussels, Brabant, Belgium; Clinique Saint Luc, Bouge, Belgium; Hôpital de Jolimont, Haine-St–Paul, Belgium; CHIREC Site Parc Leopold, Brussels, Belgium; Hôpital St-Joseph, Gilly, Belgium; Clinique Notre Dame, Charleroi, Belgium; Clinique Notre Dame, Tournai, Belgium; UCL Mont-Godinne and St-Elisabeth, Yvoir and Namur, Belgium
| | - M. Clausse
- Medical Oncology, Universite catholique de Louvain, Brussels, Brabant, Belgium; Clinique Saint Luc, Bouge, Belgium; Hôpital de Jolimont, Haine-St–Paul, Belgium; CHIREC Site Parc Leopold, Brussels, Belgium; Hôpital St-Joseph, Gilly, Belgium; Clinique Notre Dame, Charleroi, Belgium; Clinique Notre Dame, Tournai, Belgium; UCL Mont-Godinne and St-Elisabeth, Yvoir and Namur, Belgium
| | - B. Filleul
- Medical Oncology, Universite catholique de Louvain, Brussels, Brabant, Belgium; Clinique Saint Luc, Bouge, Belgium; Hôpital de Jolimont, Haine-St–Paul, Belgium; CHIREC Site Parc Leopold, Brussels, Belgium; Hôpital St-Joseph, Gilly, Belgium; Clinique Notre Dame, Charleroi, Belgium; Clinique Notre Dame, Tournai, Belgium; UCL Mont-Godinne and St-Elisabeth, Yvoir and Namur, Belgium
| | - L. Marcelis
- Medical Oncology, Universite catholique de Louvain, Brussels, Brabant, Belgium; Clinique Saint Luc, Bouge, Belgium; Hôpital de Jolimont, Haine-St–Paul, Belgium; CHIREC Site Parc Leopold, Brussels, Belgium; Hôpital St-Joseph, Gilly, Belgium; Clinique Notre Dame, Charleroi, Belgium; Clinique Notre Dame, Tournai, Belgium; UCL Mont-Godinne and St-Elisabeth, Yvoir and Namur, Belgium
| | - B. Honhon
- Medical Oncology, Universite catholique de Louvain, Brussels, Brabant, Belgium; Clinique Saint Luc, Bouge, Belgium; Hôpital de Jolimont, Haine-St–Paul, Belgium; CHIREC Site Parc Leopold, Brussels, Belgium; Hôpital St-Joseph, Gilly, Belgium; Clinique Notre Dame, Charleroi, Belgium; Clinique Notre Dame, Tournai, Belgium; UCL Mont-Godinne and St-Elisabeth, Yvoir and Namur, Belgium
| | - L. D’Hondt
- Medical Oncology, Universite catholique de Louvain, Brussels, Brabant, Belgium; Clinique Saint Luc, Bouge, Belgium; Hôpital de Jolimont, Haine-St–Paul, Belgium; CHIREC Site Parc Leopold, Brussels, Belgium; Hôpital St-Joseph, Gilly, Belgium; Clinique Notre Dame, Charleroi, Belgium; Clinique Notre Dame, Tournai, Belgium; UCL Mont-Godinne and St-Elisabeth, Yvoir and Namur, Belgium
| | - C. Dopchie
- Medical Oncology, Universite catholique de Louvain, Brussels, Brabant, Belgium; Clinique Saint Luc, Bouge, Belgium; Hôpital de Jolimont, Haine-St–Paul, Belgium; CHIREC Site Parc Leopold, Brussels, Belgium; Hôpital St-Joseph, Gilly, Belgium; Clinique Notre Dame, Charleroi, Belgium; Clinique Notre Dame, Tournai, Belgium; UCL Mont-Godinne and St-Elisabeth, Yvoir and Namur, Belgium
| | - M. Bonny
- Medical Oncology, Universite catholique de Louvain, Brussels, Brabant, Belgium; Clinique Saint Luc, Bouge, Belgium; Hôpital de Jolimont, Haine-St–Paul, Belgium; CHIREC Site Parc Leopold, Brussels, Belgium; Hôpital St-Joseph, Gilly, Belgium; Clinique Notre Dame, Charleroi, Belgium; Clinique Notre Dame, Tournai, Belgium; UCL Mont-Godinne and St-Elisabeth, Yvoir and Namur, Belgium
| | - J. Kerger
- Medical Oncology, Universite catholique de Louvain, Brussels, Brabant, Belgium; Clinique Saint Luc, Bouge, Belgium; Hôpital de Jolimont, Haine-St–Paul, Belgium; CHIREC Site Parc Leopold, Brussels, Belgium; Hôpital St-Joseph, Gilly, Belgium; Clinique Notre Dame, Charleroi, Belgium; Clinique Notre Dame, Tournai, Belgium; UCL Mont-Godinne and St-Elisabeth, Yvoir and Namur, Belgium
| |
Collapse
|